FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022000183> ?p ?o ?g. }

• W2022000183 endingPage "1791" @default.
• W2022000183 startingPage "1785" @default.
• W2022000183 abstract "Background/Purpose: Apoptotic factors inducing or preventing cell death may intrinsically govern the behavior of some tumors. Survivin is a recently described member of the inhibitor of apoptosis protein (IAP) family, that is expressed in a cell cycle–dependent manner and is found in tumors of unfavorable histology. This study examines the presence of several apoptotic factors, including survivin, in neuroblastoma (NB) tumors. Clues to survivin's function in NB are provided by examining its association with behavior and cell dynamics in tumors and cell lines. Methods: Expression of a panel of apoptosis factors were quantified in 15 NB and related tumors before chemotherapy and in 3 NB cell lines (NB7, NB10, and NB16). Survivin and other apoptotic factors, as well N-myc amplification in primary tumors was correlated with recurrent disease and outcome. Proliferation rate, apoptosis assays, cell cycle analysis, and drug- or immune-mediated cell death were assessed in cell lines and evaluated in the context of differential survivin and apoptosis gene expression. Results: All 7 tumors that went on to recur expressed survivin, whereas expression was absent in all 8 tumors that went into remission. N-myc was amplified in 4 (57.1%) of the 7 recurrent tumors. Of the 8 tumors that were cured, Fas was expressed in 3 (38%), TRAIL-R1 in 6 (75%) and tumor necrosis factor (TNF)-R1 in 8 (100%), whereas these pro-apoptotic receptors were present in only 1 (14%), 1 (14%), and 4 (57%) of the 7 tumors that went on to recur, respectively. Of the 3 cell lines, NB10 expressed the least survivin, displayed the lowest proliferation index, and had the fewest number of cells in the G2/M (mitotic) phase of the cell cycle. Furthermore, NB10 also was most sensitive to TNF-related apoptosis-inducing ligand (TRAIL) or etoposide-induced cell death. Conclusions: In primary NB tumors, survivin expression was associated with tumors of high risk and unfavorable prognosis, whereas pro-apoptotic receptor expression was more abundant in tumors of favorable prognosis. In this small series, survivin expression appeared to be more predictive of recurrent disease than N-myc amplification. In cell lines, survivin expression was cell cycle dependent, and its expression was associated with greater proliferation rates and greater resistance to drug- or immune-mediated cell death. Survivin expression may become a useful prognostic marker in NB and could be a potential target for the treatment of this tumor. J Pediatr Surg 36:1785-1791. Copyright © 2001 by W.B. Saunders Company." @default.
• W2022000183 created "2016-06-24" @default.
• W2022000183 creator A5014584828 @default.
• W2022000183 creator A5021224036 @default.
• W2022000183 creator A5034208174 @default.
• W2022000183 creator A5044885983 @default.
• W2022000183 creator A5063456712 @default.
• W2022000183 creator A5068177332 @default.
• W2022000183 creator A5083455823 @default.
• W2022000183 date "2001-12-01" @default.
• W2022000183 modified "2023-09-27" @default.
• W2022000183 title "The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma" @default.
• W2022000183 cites W1595083214 @default.
• W2022000183 cites W1598719623 @default.
• W2022000183 cites W1972304655 @default.
• W2022000183 cites W1991865867 @default.
• W2022000183 cites W1992045438 @default.
• W2022000183 cites W2002503549 @default.
• W2022000183 cites W2012219845 @default.
• W2022000183 cites W2024280594 @default.
• W2022000183 cites W2024545138 @default.
• W2022000183 cites W2035523654 @default.
• W2022000183 cites W2059644739 @default.
• W2022000183 cites W2089476060 @default.
• W2022000183 cites W2092196409 @default.
• W2022000183 cites W2092508425 @default.
• W2022000183 cites W2094985040 @default.
• W2022000183 cites W2105186639 @default.
• W2022000183 cites W2113505777 @default.
• W2022000183 cites W2129589968 @default.
• W2022000183 cites W2314256590 @default.
• W2022000183 cites W2329506722 @default.
• W2022000183 cites W2330923897 @default.
• W2022000183 doi "https://doi.org/10.1053/jpsu.2001.28839" @default.
• W2022000183 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11733907" @default.
• W2022000183 hasPublicationYear "2001" @default.
• W2022000183 type Work @default.
• W2022000183 sameAs 2022000183 @default.
• W2022000183 citedByCount "92" @default.
• W2022000183 countsByYear W20220001832012 @default.
• W2022000183 countsByYear W20220001832013 @default.
• W2022000183 countsByYear W20220001832014 @default.
• W2022000183 countsByYear W20220001832015 @default.
• W2022000183 countsByYear W20220001832016 @default.
• W2022000183 countsByYear W20220001832017 @default.
• W2022000183 countsByYear W20220001832018 @default.
• W2022000183 countsByYear W20220001832019 @default.
• W2022000183 countsByYear W20220001832020 @default.
• W2022000183 countsByYear W20220001832021 @default.
• W2022000183 countsByYear W20220001832022 @default.
• W2022000183 countsByYear W20220001832023 @default.
• W2022000183 crossrefType "journal-article" @default.
• W2022000183 hasAuthorship W2022000183A5014584828 @default.
• W2022000183 hasAuthorship W2022000183A5021224036 @default.
• W2022000183 hasAuthorship W2022000183A5034208174 @default.
• W2022000183 hasAuthorship W2022000183A5044885983 @default.
• W2022000183 hasAuthorship W2022000183A5063456712 @default.
• W2022000183 hasAuthorship W2022000183A5068177332 @default.
• W2022000183 hasAuthorship W2022000183A5083455823 @default.
• W2022000183 hasConcept C121608353 @default.
• W2022000183 hasConcept C126322002 @default.
• W2022000183 hasConcept C17991360 @default.
• W2022000183 hasConcept C190283241 @default.
• W2022000183 hasConcept C203014093 @default.
• W2022000183 hasConcept C2775975398 @default.
• W2022000183 hasConcept C2776715637 @default.
• W2022000183 hasConcept C2777408456 @default.
• W2022000183 hasConcept C29537977 @default.
• W2022000183 hasConcept C31573885 @default.
• W2022000183 hasConcept C502942594 @default.
• W2022000183 hasConcept C54355233 @default.
• W2022000183 hasConcept C55493867 @default.
• W2022000183 hasConcept C66008609 @default.
• W2022000183 hasConcept C71924100 @default.
• W2022000183 hasConcept C81885089 @default.
• W2022000183 hasConcept C86803240 @default.
• W2022000183 hasConceptScore W2022000183C121608353 @default.
• W2022000183 hasConceptScore W2022000183C126322002 @default.
• W2022000183 hasConceptScore W2022000183C17991360 @default.
• W2022000183 hasConceptScore W2022000183C190283241 @default.
• W2022000183 hasConceptScore W2022000183C203014093 @default.
• W2022000183 hasConceptScore W2022000183C2775975398 @default.
• W2022000183 hasConceptScore W2022000183C2776715637 @default.
• W2022000183 hasConceptScore W2022000183C2777408456 @default.
• W2022000183 hasConceptScore W2022000183C29537977 @default.
• W2022000183 hasConceptScore W2022000183C31573885 @default.
• W2022000183 hasConceptScore W2022000183C502942594 @default.
• W2022000183 hasConceptScore W2022000183C54355233 @default.
• W2022000183 hasConceptScore W2022000183C55493867 @default.
• W2022000183 hasConceptScore W2022000183C66008609 @default.
• W2022000183 hasConceptScore W2022000183C71924100 @default.
• W2022000183 hasConceptScore W2022000183C81885089 @default.
• W2022000183 hasConceptScore W2022000183C86803240 @default.
• W2022000183 hasIssue "12" @default.
• W2022000183 hasLocation W20220001831 @default.
• W2022000183 hasLocation W20220001832 @default.
• W2022000183 hasOpenAccess W2022000183 @default.
• W2022000183 hasPrimaryLocation W20220001831 @default.

• next